ImageneBio, Inc. (IMA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. ImageneBio, Inc. (formerly Ikena Oncology, Inc.) is a clinical-stage biopharmaceutical company formed via a reverse recapitalization merger with Legacy Inmagene Biopharmaceuticals, completed on July 25, 2025. The company focuses exclusively on the development of olevaprubart (formerly IMG-007), a non-depleting anti-OX40 monoclonal antibody for immunological and inflammatory diseases, specifically atopic dermatitis (AD) and alopecia areata (AA). All non-OX40 assets were divested in connection with the merger.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0.8M |
| Net Loss | $(10.2M) | $(7.6M) | $(20.8M) | $(13.7M) |
| Operating Expenses | $11.8M | $7.4M | $23.9M | $14.2M |
| Cash & Equivalents | $94.7M (as of June 30, 2026) | |||
| Marketable Securities | $41.5M (as of June 30, 2026) | |||
| Total Liquidity | $136.2M (as of June 30, 2026) | |||
| Accumulated Deficit | $(250.9M) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: The company generated no revenue in Q2 2026 or YTD 2026, compared to $0.8M in license revenue in YTD 2025. This is due to the divestiture of non-OX40 programs in July 2025.
- Expense Increase: Operating expenses increased significantly year-over-year.
- R&D: Increased to $6.7M (Q2) and $12.6M (YTD) from $5.7M and $9.7M, respectively, driven by Phase 2b clinical trial costs for AD and increased personnel costs.
- G&A: Increased to $5.1M (Q2) and $11.2M (YTD) from $1.7M and $4.5M, respectively. Increases are attributed to public company compliance costs, legal fees, stock-based compensation, and retention/severance costs.
- Capital Raise: In April 2026, the company completed a private placement of pre-funded warrants, raising gross proceeds of $30.0M.
- Interest Income: Interest income turned positive ($1.2M in Q2) due to higher cash balances and interest rates, compared to interest expense in the prior year.
Guidance, Outlook, and Risks
- Clinical Outlook:
- Atopic Dermatitis (AD): Phase 2b dose-finding study is ongoing; topline data expected in Q4 2027.
- Alopecia Areata (AA): Phase 2 study expected to initiate by end of 2026, with initial data expected in 2028.
- Liquidity: Management believes current cash, cash equivalents, and marketable securities ($136.2M) are sufficient to fund operations for at least the next 12 months. However, substantial additional funding will be required for future development and commercialization.
- Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to segregation of duties (specifically regarding journal entries and account reconciliations). This weakness was not remediated as of June 30, 2026.
- Key Risks:
- Dependence on a single product candidate (olevaprubart).
- Reliance on third-party manufacturers (WuXi Biologics) located in China, subject to trade restrictions and the BIOSECURE Act.
- Need for significant additional capital; potential dilution to shareholders.
- Regulatory uncertainty and clinical trial risks.
Investor Verification Checklist
- Verify the status and timeline of the Phase 2b AD study and the initiation of the AA Phase 2 study.
- Monitor the remediation plan for the material weakness in internal controls over financial reporting.
- Assess the impact of the BIOSECURE Act and potential tariffs on the supply chain for manufacturing in China.
- Review the terms of the Hutchmed license agreement regarding milestone payments and royalties.
- Track cash burn rate relative to the $136.2M liquidity position to determine the timing of future capital raises.